Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | CA2 | P00918 | 5/20 | 0.43 |
| ▸ | CA9 | Q16790 | 5/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25640010 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL7263734 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL436333 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL26032485 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL12238318 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL13699509 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL25257785 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL14671684 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL22939187 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 | |
| SCHEMBL25639770 | 1.00 | MEN1 (0.49) | MEN1KMT2AGAATDP1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250135043-A1 | DUAL-TARGETING COMPOUND FOR FIBROBLAST ACTIVATION PROTEIN (FAP) AND INTEGRIN avB3, PREPARATION METHOD THEREFOR AND USE THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO., LTD. (CN) | 2025-05-01 | — | — | US | claimed |
| US-11992536-B2 | Dual-targeting compound and preparation method and application thereof | YANTAI LANNACHENG BIOTECHNOLOGY CO., LTD. (CN) | 2024-05-28 | — | — | US | claimed |
| US-20240131205-A1 | DUAL-TARGETING COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | YANTAI LANNACHENG BIOTECHNOLOGY CO., LTD. (CN) | 2024-04-25 | — | — | US | claimed |
| WO-2024067531-A1 | DUAL-TARGETING COMPOUND AGAINST FIBROBLAST ACTIVATION PROTEIN FAP AND INTEGRIN αVβ3, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 烟台蓝纳成生物技术有限公司 | 2024-04-04 | — | — | WO | claimed |
| EP-4253402-A1 | DUAL-TARGETING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Yantai Lannacheng Biotechnology Co., Ltd. (CN) | 2023-10-04 | — | — | EP | claimed |
| CN-116751259-A | Fibroblast activation protein FAP and integrin alpha v β 3 Dual targeting compounds and methods of making the same | 烟台蓝纳成生物技术有限公司 | 2023-09-15 | — | — | CN | claimed |
| WO-2023098920-A1 | DUAL-TARGETING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 烟台蓝纳成生物技术有限公司 | 2023-06-08 | — | — | WO | claimed |
| CN-115505032-A | Fibroblast activation protein FAP and integrin alpha v β 3 Dual-targeting compound and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-115286697-B | Dual-targeting compound and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2022-12-13 | — | — | CN | claimed |
| CN-115286697-A | Dual-targeting compound and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2022-11-04 | — | — | CN | claimed |
| US-12637473-B2 | MDM2 protein degraders | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4734988-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF USE THEREOF | The Board of Trustees of the Leland Stanford Junior University (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
| US-7455855-B2 | Delivering substance and drug delivery system using the same | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637473-B2 | MDM2 protein degraders | MDM2, TP53, TP53BP1 | MEN1 1485/4885KMT2A 1892/4885GAA 1301/4885 |
| US-20250135043-A1 | DUAL-TARGETING COMPOUND FOR FIBROBLAST ACTIVATION PROTEIN (FAP) AND INTEGRIN avB3, PREPARATION METHOD THEREFOR AND USE THEREOF | FAP, ITGAV, ITGB3 | MEN1 1988/4885KMT2A 4235/4885GAA 264/4885 |
| US-20240131205-A1 | DUAL-TARGETING COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | ITGAV, ITGA2, ITGB2 | MEN1 370/4885KMT2A 2352/4885GAA 224/4885 |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | MEN1 486/4885KMT2A 3995/4885GAA 213/4885 |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | CCR1, CCRL2, CCR3 | MEN1 2070/4885KMT2A 4235/4885GAA 4139/4885 |
| US-20260137819-A1 | FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF | FSHR, GNRHR, LHCGR | MEN1 688/4885KMT2A 1938/4885GAA 4537/4885 |
| US-11992536-B2 | Dual-targeting compound and preparation method and application thereof | ITGAV, ITGB1, ITGB2 | MEN1 325/4885KMT2A 2465/4885GAA 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.